JKOR

**JKOR** appears to be an investigational synthetic broad-spectrum antiviral compound reported by PanBiokem. Publicly available information is very limited. The most specific description located indicates that JKOR showed dose-dependent antiviral activity in preclinical screening against multiple enveloped respiratory viruses, including coronaviruses and influenza viruses, but no well-validated molecular target, mechanism of action, formulation, route, developer program details, or clinical development record could be confirmed from authoritative primary sources. Based on the available evidence, JKOR should be treated as an early preclinical small-molecule antiviral candidate with an incompletely characterized mechanism.